These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15334700)

  • 61. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
    Amarantidis K; Xenidis N; Chelis L; Chamalidou E; Dimopoulos P; Michailidis P; Tentes A; Deftereos S; Karanikas M; Karayiannakis A; Kakolyris S
    Oncology; 2011; 80(5-6):359-65. PubMed ID: 21811088
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [A randomized controlled trail of taxol-based combination regimens for advanced gastric cancer].
    Yang JW; Chen YG; Chen Q; Fan NF; Guo ZQ; Cai XC; Wu XA; Xu S; Lu X; Zhang YH; Ouyang XN
    Ai Zheng; 2005 Dec; 24(12):1531-6. PubMed ID: 16351808
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Efficacy of oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy for local advanced gastric cancer].
    Shao ZY; Zhang JD
    Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(36):2547-9. PubMed ID: 19080647
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer.
    Inadomi K; Kusaba H; Matsushita Y; Tanaka R; Mitsugi K; Arimizu K; Hirano G; Makiyama A; Ohmura H; Uchino K; Hanamura F; Shibata Y; Kuwayama M; Esaki T; Takayoshi K; Arita S; Ariyama H; Akashi K; Baba E
    Anticancer Res; 2017 May; 37(5):2663-2671. PubMed ID: 28476842
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [FOLFOX4 regimen versus DP(O)F regimen for advanced gastric cancer].
    Wu F; Zhang HG; Ran FW; Zhang XR; Shi YK
    Ai Zheng; 2008 Apr; 27(4):413-7. PubMed ID: 18423129
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy.
    Saeki H; Emi Y; Oki E; Tokunaga S; Kakeji Y; Akagi Y; Baba H; Baba E; Maehara Y;
    BMC Cancer; 2018 Jan; 18(1):57. PubMed ID: 29310611
    [TBL] [Abstract][Full Text] [Related]  

  • 67. MG-132 inhibits telomerase activity, induces apoptosis and G(1) arrest associated with upregulated p27kip1 expression and downregulated survivin expression in gastric carcinoma cells.
    Zhang W; Tong Q; Li S; Wang X; Wang Q
    Cancer Invest; 2008 Dec; 26(10):1032-6. PubMed ID: 19093261
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.
    Comella P; Lorusso V; Maiorino L; Casaretti R; Cannone M; Massidda B; Putzu C; Leo S; Roselli M; Mancarella S; Palmeri S; Greco E; Vessia G; Sandomenico C; Franco L
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):893-9. PubMed ID: 19189106
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Induction of apoptosis of human gastric carcinoma SGC-7901 cell line by 5, 7-dihydroxy-8-nitrochrysin in vitro.
    Ai XH; Zheng X; Tang XQ; Sun L; Zhang YQ; Qin Y; Liu HQ; Xia H; Cao JG
    World J Gastroenterol; 2007 Jul; 13(28):3824-8. PubMed ID: 17657836
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer.
    Liu C; Sun Q; Hang X; Zhong B; Wang D
    Anticancer Drugs; 2008 Sep; 19(8):825-31. PubMed ID: 18690095
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 72. EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells.
    Wen Q; Chen Z; Chen Z; Chen J; Wang R; Huang C; Yuan W
    Oncotarget; 2017 Jul; 8(29):47998-48011. PubMed ID: 28624791
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Chronomodulated chemotherapy of oxaliplatin, 5-fluorouracil and folinic acid for advanced gastric cancer].
    Lu JW; Zhou ZF; Yin BJ; Liu DL; Feng JF; Zhu LJ; Pan LX
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):695-7. PubMed ID: 16438895
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
    Louvet C; André T; Tigaud JM; Gamelin E; Douillard JY; Brunet R; François E; Jacob JH; Levoir D; Taamma A; Rougier P; Cvitkovic E; de Gramont A
    J Clin Oncol; 2002 Dec; 20(23):4543-8. PubMed ID: 12454110
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A molecular biological study of anti-tumor mechanisms of an anti-cancer agent Oxaliplatin against established human gastric cancer cell lines.
    Eriguchi M; Nonaka Y; Yanagie H; Yoshizaki I; Takeda Y; Sekiguchi M
    Biomed Pharmacother; 2003 Nov; 57(9):412-5. PubMed ID: 14652166
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Down-Regulating Receptor Interacting Protein Kinase 1 (RIP1) Promotes Oxaliplatin-Induced Tca8113 Cell Apoptosis.
    Shan B; Ma F; Wang M; Xu X
    Med Sci Monit; 2015 Oct; 21():3089-94. PubMed ID: 26460489
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tributyrin inhibits human gastric cancer SGC-7901 cell growth by inducing apoptosis and DNA synthesis arrest.
    Yan J; Xu YH
    World J Gastroenterol; 2003 Apr; 9(4):660-4. PubMed ID: 12679905
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death.
    Tassone P; Tagliaferri P; Galea E; Palmieri C; Bonelli P; Martelli ML; Tuccillo F; Turco MC; Venuta S
    Eur J Cancer; 2002 May; 38(8):1141-7. PubMed ID: 12008204
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Combination treatment with oxaliplatin and mangiferin causes increased apoptosis and downregulation of NFκB in cancer cell lines.
    du Plessis-Stoman D; du Preez J; van de Venter M
    Afr J Tradit Complement Altern Med; 2011; 8(2):177-84. PubMed ID: 22238500
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pilot study for preoperative administration of l-OHP to patients with advanced scirrhous type gastric cancer.
    Eriguchi M; Osada I; Fujii Y; Takeda Y; Yoshizaki I; Akiyama N; Yanagie H; Sekiguchi M; Kizu R; Matsushita H; Mathé G
    Biomed Pharmacother; 1997; 51(5):217-20. PubMed ID: 9247019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.